New vaccine-chemo combo takes on hard-to-treat neuroendocrine cancers
NCT ID NCT06202066
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 30 times
Summary
This study tests whether adding a cancer vaccine (SurVaxM) to standard chemotherapy (temozolomide) helps control advanced neuroendocrine tumors that are growing. About 60 adults with metastatic disease will receive either the combination or chemo alone. The goal is to see if the vaccine boosts the immune system to fight cancer and extends time without tumor growth.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT SOLID NEOPLASM are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Roswell Park Cancer Institute
RECRUITINGBuffalo, New York, 14263, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.